Using the mitosis-specific marker anti-phosphohistone H3 to assess mitosis in pulmonary neuroendocrine carcinomas

American Journal of Clinical Pathology

Volumn 136, Issue 2, 2011, Pages 252-259

  Tsuta, Koji ^a,b   Liu, Diane C ^a   Kalhor, Neda ^a   Wistuba, Ignacio I ^a   Moran, Cesar A ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b NATIONAL CANCER CENTER HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

HISTONE H3; KI 67 ANTIGEN;

ARTICLE; BRONCHUS CARCINOID; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LABELING INDEX; LUNG SMALL CELL CANCER; MITOSIS INDEX; NEUROENDOCRINE TUMOR; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; SURVIVAL RATE; TUMOR DIFFERENTIATION;

ANTIBODIES; CARCINOMA, NEUROENDOCRINE; HISTONES; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MITOSIS; PROGNOSIS; RETROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL;

EID: 79960983495     PISSN: 00029173     EISSN: 19437722     Source Type: Journal    
DOI: 10.1309/AJCPDXFOPXGEF0RP     Document Type: Article

References (38)

1. Gustafsson BI, Kidd M, Chan A, et al. Bronchopulmonary neuroendocrine tumors. Cancer. 2008;113:5-21. (Pubitemid 351976381)
2. Travis WD, Rush W, Flieder DB, et al. Survival analysis of 200 pulmonary neuroendocrine tumors with clarification of criteria for atypical carcinoid and its separation from typical carcinoid. Am J Surg Pathol. 1998;22:934-944. (Pubitemid 28364493)
3. Beasley MB, Thunnissen FB, Hasleton PS, et al. Carcinoid tumour. In: Travis WD, Brambilla E, Müller-Hermelink HK, et al, eds. WHO Classification of Tumours: Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart. Lyon, France: IARC Press; 2004:59-62.
4. Travis WD, Linnoila RI, Tsokos MG, et al. Neuroendocrine tumors of the lung with proposed criteria for large-cell neuroendocrine carcinoma: an ultrastructural, immunohistochemical, and flow cytometric study of 35 cases. Am J Surg Pathol. 1991;15:529-553.
5. Beasley MB, Thunnissen FB, Brambilla E, et al. Pulmonary atypical carcinoid: predictors of survival in 106 cases. Hum Pathol. 2000;31:1255-1265.
6. Rugge M, Fassan M, Clemente R, et al. Bronchopulmonary carcinoid: phenotype and long-term outcome in a single-institution series of Italian patients. Clin Cancer Res. 2008;14:149-154. (Pubitemid 351377990)
7. Van Diest PJ, Baak JPA, Matze-Cok P, et al. Reproducibility of mitosis counting in 2,469 breast cancer specimens: results from the Multicenter Morphometric Mammary Carcinoma Project. Hum Pathol. 1992;23:603-607.
8. Molenaar WM, Plaat BEC, Berends ER, et al. Observer reliability in assessment of mitotic activity and MIB-1-determined proliferation rate in pediatric sarcomas. Ann Diagn Pathol. 2000;4:228-235.
9. Tsuta K, Raso MG, Kalhor N, et al. Histologic features of low- and intermediate-grade neuroendocrine carcinoma (typical and atypical carcinoid tumors) of the lung. Lung Cancer. 2011;71:34-41.
10. 2 and spreads in an ordered fashion coincident with mitotic chromosome condensation. Chromosoma. 1997;106:348-360.
11. Hendzel MJ, Nishioka WK, Raymond Y, et al. Chromatin condensation is not associated with apoptosis. J Biol Chem. 1998;18:24470-24478. (Pubitemid 28454940)
12. Ribalta T, McCutcheon IE, Aldape KD, et al. The mitosis-specific antibody anti-phosphohistone-H3 (PHH3) facilitates rapid reliable grading of meningiomas according to WHO 2000 criteria. Am J Surg Pathol. 2004;28:1532-1536. (Pubitemid 39425522)
13. Tapia C, Kutzner H, Mentzel T, et al. Two mitosis-specific antibodies, MPM-2 and phospho-histone H3 (Ser28), allow rapid and precise determination of mitotic activity. Am J Surg Pathol. 2006;30:83-89. (Pubitemid 43740213)
14. Colman H, Giannini C, Huang L, et al. Assessment and prognostic significance of mitotic index using the mitosis marker phospho-histone H3 in low and intermediate-grade infiltrating astrocytomas. Am J Surg Pathol. 2006;30:657-664. (Pubitemid 44265019)
15. Kim YJ, Ketter R, Steudel WI, et al. Prognostic significance of the mitotic index using the mitosis marker anti-phosphohistone H3 in meningiomas. Am J Clin Pathol. 2007;128:118-125. (Pubitemid 47121724)
16. Nasr MR, El-Zammar O. Comparison of pHH3, Ki-67, and survivin immunoreactivity in benign and malignant melanocytic lesions. Am J Dermatopathol. 2008;30:117-122. (Pubitemid 351441982)
17. Skaland I, Janssen EA, Gudlaugsson E, et al. Phosphohistone H3 expression has much stronger prognostic value than classical prognosticators in invasive lymph node-negative breast cancer patients less than 55 years of age. Mod Pathol. 2007;20:1307-1315. (Pubitemid 350126856)
18. Veras E, Malpica A, Deavers MT, et al. Mitosis-specific marker phospho-histone H3 in the assessment of mitotic index in uterine smooth muscle tumors: a pilot study. Int J Gynecol Pathol. 2009;28:316-321.
19. Angi M, Damato B, Kalirai H, et al. Immunohistochemical assessment of mitotic count in uveal melanoma. Acta Ophthalmol. 2011;89:e155-e160. doi:10.1111/j.1755- 3768.2009.01769.x.
20. Bossard C, Jarry A, Colombeix C, et al. Phosphohistone H3 labelling for histoprognostic grading of breast adenocarcinomas and computer-assisted determination of mitotic index. J Clin Pathol. 2006;59:706-710. (Pubitemid 44048778)
21. Fukushima S, Terasaki M, Sakata K, et al. Sensitivity and usefulness of anti-phosphohistone-H3 antibody immunostaining for counting mitotic figures in meningioma cases. Brain Tumor Pathol. 2009;26:51-57.
22. Gatter KC, Dunnill MS, Gerdes J, et al. New approach to assessing lung tumours in man. J Clin Pathol. 1986;39:590-593. (Pubitemid 16069661)
23. Soomro IN, Whimster WF. Growth fraction in lung tumours determined by Ki67 immunostaining and comparison with AgNOR scores. J Pathol. 1990;162:217-222.
24. Tungekar MF, Gatter KC, Dunnill MS, et al. Ki-67 immunostaining and survival in operable lung cancer. Histopathology. 1991;19:545-550.
25. Barbareschi M, Girlando S, Mauri FA, et al. Tumour suppressor gene products, proliferation, and differentiation markers in lung neuroendocrine neoplasms. J Pathol. 1992;166:343-350.
26. Hayashi Y, Fukayama M, Koike M, et al. Cell-cycle analysis detecting endogenous nuclear antigens: comparison with BrdU-in vivo labeling and an application to lung tumors. Acta Pathol Jpn. 1993;43:313-319. (Pubitemid 23174983)
27. Kawai T, Suzuki M, Kono S, et al. Proliferating cell nuclear antigen and Ki-67 in lung carcinoma: correlation with DNA flow cytometric analysis. Cancer. 1994;74:2468-2475. (Pubitemid 24320850)
28. Costes V, Marty-Ane C, Picot MC, et al. Typical and atypical bronchopulmonary carcinoid tumors: a clinicopathologic and Ki-67-labeling study. Hum Pathol. 1995;26:740-745.
29. Bohm J, Koch S, Gais P, et al. Prognostic value of MIB-1 in neuroendocrine tumours of the lung. J Pathol. 1996;178:402-409. (Pubitemid 26146796)
30. Rusch VW, Klimstra DS, Venkatraman ES. Molecular markers help characterize neuroendocrine lung tumors. Ann Thorac Surg. 1996;62:798-809.
31. Laitinen KL, Soini Y, Mattila J, et al. Atypical bronchopulmonary carcinoids show a tendency toward increased apoptotic and proliferative activity. Cancer. 2000;88:1590-1598. (Pubitemid 30183144)
32. Arbiser ZK, Arbiser JL, Cohen C, et al. Neuroendocrine lung tumors: grade correlates with proliferation but not angiogenesis. Mod Pathol. 2001;14:1195-1199. (Pubitemid 33151160)
33. Lin O, Olgac S, Green I, et al. Immunohistochemical staining of cytologic smears with MIB-1 helps distinguish low-grade from high-grade neuroendocrine neoplasms. Am J Clin Pathol. 2003;120:209-216. (Pubitemid 37046355)
34. Gerdes J, Lemke H, Baisch H, et al. Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol. 1984;133:1710-1715. (Pubitemid 14035254)
35. Davenport RD. Diagnostic value of crush artifact in cytologic specimens: occurrence in small cell carcinoma of the lung. Acta Cytol. 1990;34:502-504. (Pubitemid 20228843)
36. Aslan DL, Gulbahce HE, Pambuccian SE, et al. Ki-67 immunoreactivity in the differential diagnosis of pulmonary neuroendocrine neoplasms in specimens with extensive crush artifact. Am J Clin Pathol. 2005;123:874-878. (Pubitemid 40740685)
37. Pelosi G, Rodriguez J, Viale G, et al. Typical and atypical pulmonary carcinoid tumor overdiagnosed as small-cell carcinoma on biopsy specimens: a major pitfall in the management of lung cancer patients. Am J Surg Pathol. 2005;29:179-187. (Pubitemid 40170635)
38. Spiro SG, Porter JC. Lung cancer: where are we today? current advances in staging and nonsurgical treatment. Am J Respir Crit Care Med. 2002;166:1166-1196. (Pubitemid 35222595)